In The Lancet Oncology, Joseph C Del Paggio and colleagues1 examine expenditures for the ten drugs with the highest expenditure between 2012 and 2022 in Ontario, Canada. Studies with this level of granularity are rare, and even more so when conducted longitudinally. Pairing these expenditures with clinical outcomes makes these results even more informative and relevant.